“…Despite the improvements in outcome, isolated nodal basin recurrence was worse after adjuvant ST compared to ND (6% vs 1%, respectively). 3 The literature lacks strong evidence on the added value of concurrent adjuvant RT and adjuvant ST. Salama et al 4 prospectively investigated the feasibility of concurrent Ipilimumab and RT in the adjuvant, neoadjuvant or definitive therapy for unresectable stage III melanoma. Twenty-four patients were enrolled: 13 in the adjuvant group (cohort 1) and 11 in the neoadjuvant/ definitive group (cohort 2).…”